Third Harmonic Bio - About the company
Third Harmonic Bio is a public company based in Cambridge (United States), founded in 2019. It operates as a Developer therapeutics to treat allergy and inflammatory diseases. Third Harmonic Bio has raised $205M in funding from investors like Atlas Venture, General Atlantic and Orbimed. The company has 2839 active competitors, including 974 funded and 674 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Juno Therapeutics and Revolution Medicines.
Company Details
Developer therapeutics to treat allergy and inflammatory diseases. The company's product line include THB001 is an oral small-molecule KIT inhibitor for the treatment of severe allergic and mast cell-driven inflammatory conditions like Chronic Inducible Urticaria, airway, and gastrointestinal tract indications.
- Website
- Social
- Email ID
- @thirdharmonicbio.com
- Registered Address
- Cambridge (United States)
Key Metrics
Founded Year
2019
Location
Cambridge, United States
Stage
Public
Total Funding
in 3 rounds
Latest Funding Round
Investors
Ranked
220th among
Employee Count
as on Dec 31, 2022
Similar Companies
Incyte &
Exit Details
Public
Legal entities associated with Third Harmonic Bio
Third Harmonic Bio is associated with 2 legal entities given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
CIN: 1923840 United States, Deadpooled | Apr 24, 2019 | - | - | - |
CIN: 83-4553503 United States, Active | Dec 31, 2018 | - | 28 (as on Dec 31, 2022) | - |
Get your free copy of Third Harmonic Bio's company profile
Third Harmonic Bio's funding and investors
Third Harmonic Bio has raised a total funding of $205M over 3 rounds. Its first funding round was on Jan 2019. Its latest funding round was a Series B round on Feb 16, 2022 for $155M. 8 investors participated in its latest round, lead by General Atlantic and BVF Partners.
Third Harmonic Bio has 10 institutional investors including Atlas Venture, General Atlantic and Orbimed.
Here is the list of recent funding rounds of Third Harmonic Bio:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Feb 16, 2022 | $155M | Series B | 6214798 | 9827295 | General Atlantic, BVF Partners, and |
2019 | $50M | Series A | 9507 | 5945 | Atlas Venture, Orbimed, and |
Jan 2019 | Undisclosed | Seed | 1582737 | 8305979 |
Access funding benchmarks and valuations. Sign up today!View details of Third Harmonic Bio's funding rounds and investors
Third Harmonic Bio's founders and board of directors
Third Harmonic Bio's employee count trend
Third Harmonic Bio has 28 employees as of Dec 22. Here is Third Harmonic Bio's employee count trend over the years:
Uncover Third Harmonic Bio's growth story! Sign up today!
Access 秘密研究所 on any website
Our Google Chrome extension lets you view company details while browsing their websites
Third Harmonic Bio's Competitors and alternates
Top competitors of Third Harmonic Bio include Jazz Pharmaceuticals, Juno Therapeutics and Revolution Medicines. Here is the list of Top 10 competitors of Third Harmonic Bio, ranked by 秘密研究所 score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Overall Rank | Company Details | Short Description | Total Funding | Investors | 秘密研究所 Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | Oak Hill, InterWest Partners听&补尘辫;听 | 80/100 |
2nd | Juno Therapeutics 2013, Seattle (United States), Acquired | CAR T-Cell and T-Cell Receptor-based immunotherapies for the treatment of cancer. | $317M | 73/100 | |
3rd |  Revolution Medicines 2014, Redwood City (United States), Public | Developer of therapies for treating cancer | $181M | BB Biotech, Colt Ventures听&补尘辫;听 | 72/100 |
4th | Incyte 1991, Wilmington (United States), Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | 71/100 | |
5th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Ridgeback Capital Management, Roche听&补尘辫;听 | 71/100 |
6th | Developer of antibody-based drugs to treat autoimmune diseases and cancer | $61.9M | BB Biotech, Avoro Capital Advisors听&补尘辫;听 | 71/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 71/100 | |
8th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 70/100 | |
9th | _1545299782322.png?height=40&width=40){kind=logo} Erasca 2018, San Diego (United States), Public | Developer of small molecule based therapeutics for cancer | $300M | Colt Ventures, Orbimed听&补尘辫;听 | 69/100 |
10th |  Allogene Therapeutics 2018, San Francisco (United States), Public | Developer of chimeric antigen receptor cell therapy to treat cancer | $532M | Avoro Capital Advisors, TPG听&补尘辫;听 | 68/100 |
220th |  2019, Cambridge (United States), Public | Developer therapeutics to treat allergy and inflammatory diseases | $205M | Orbimed, BVF Partners听&补尘辫;听 | 54/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Third Harmonic Bio's competitors? Click to see the top ones
Third Harmonic Bio's Investments and acquisitions
Third Harmonic Bio has made no investments or acquisitions yet.
Reports related to Third Harmonic Bio
Here is the latest report on Third Harmonic Bio's sector:
View
News related to Third Harmonic Bio
Media has covered Third Harmonic Bio for a total of 7 events in the last 1 year, 4 of them have been about company updates and 1 about people movement.
鈥�
鈥�
EndPoints News鈥�Apr 14, 2025鈥�Third Harmonic Bio
鈥�
Seeking Alpha鈥�Apr 14, 2025鈥�Third Harmonic Bio
鈥�
GlobeNewswire鈥�Mar 27, 2025鈥�Third Harmonic Bio
鈥�
Benzinga鈥�Feb 13, 2025鈥�Third Harmonic Bio
鈥�
GlobeNewswire鈥�Nov 07, 2024鈥�Third Harmonic Bio
鈥�
GlobeNewswire鈥�Aug 08, 2024鈥�Third Harmonic Bio
鈥�
Seeking Alpha鈥�May 16, 2024鈥�Third Harmonic Bio
鈥�
GlobeNewswire鈥�May 15, 2024鈥�Third Harmonic Bio
鈥�
Investing鈥�Apr 09, 2024鈥�Third Harmonic Bio
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQ's about Third Harmonic Bio
Explore our recently published companies
- Tenevia - Meylan based, 2012 founded, Unfunded company
- Chat Diagram - Singapore based, 2024 founded, Unfunded company
- BuildQ - Sacramento based, 2024 founded, Unfunded company
